Moderna shares drop after reports that cancer vaccine trial data leaked before the full results are officially released. Multiple outlets say the move comes despite indications that the findings are positive based on Wall Street expectations.
Across coverage, CNBC, MarketWatch, and others describe a “sell-the-news” type reaction and focus on the timing—investors react as anticipated Phase 3 data arrives. BioPharma Dive and MarketWatch add that Moderna and partner Merck are expected to present the Phase 3 information at an upcoming medical conference, underscoring how quickly the market turns from anticipation to disclosure.
The shared context in the reporting is a melanoma study testing a combination of Moderna’s vaccine with Merck’s immunotherapy, Keytruda. BioPharma Dive says the combination reduces the risk of relapse or death by 42% and that the study meets expectations. Forbes emphasizes the scale of the market response, noting a sharp reversal following an earlier stock rally linked to optimism around the company’s personalized cancer vaccine.
